All Industries

Olympio Metals hums like a Cadillac after its latest lithium results

OLYMPIO METALS LIMITED

Olympio Metals Ltd (ASX:OLY) managing director Sean Delaney sits down with Proactive’s Jonathan Jackson to discuss recent progress at the Cadillac Lithium Project in Quebec, Canada. The company has completed a 23-hole, 2,715-metre diamond drilling program across four pegmatite dykes, uncovering significant lithium-caesium-tantalum (LCT) geochemical fractionation trends that underscore the area's lithium prospects. Notable discoveries include spodumene with grades reaching 2.3% lithium oxide in the Dyke B area, expanding the project's known lithium potential. This drilling effort, combined with prior surface sampling, indicates that the LCT pegmatites cover a larger area than initially anticipated, setting the stage for expanded regional exploration. Olympio has secured $1.1 million through Canadian Flow-Through Shares and is well-prepared for the upcoming field season. This funding will support continued exploration across their 190-square-kilometre landholding, where numerous high-priority pegmatite targets await testing. The recent drilling has delineated two distinct zones of fractionated pegmatites, hinting at multiple generations of LCT mineralised intrusions. These findings will guide the company's exploration strategy, focusing on areas with elevated potassium-rubidium fractionation trends linked to lithium mineralisation. With over 400 known pegmatites in the Cadillac Project area, Olympio is poised to advance its exploration activities, leveraging the latest geological insights to target high-priority areas in the coming weeks. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 jonathan@proactiveinvestors.com

April 12, 2024 03:45 PM Eastern Daylight Time

Video

Farm Forward Investigation Reveals America’s First “Certified Regenerative Dairy Farm” Alexandre Farm Abuses and Neglects Animals

Farm Forward

In an extensive investigation released today, Farm Forward revealed that Alexandre Family Farm —a famous, widely endorsed organic dairy farm in California that sells at Whole Foods and other major grocery chains—routinely abuses and neglects its animals, sells diseased animals for human consumption, and pollutes the environment. Despite clear evidence of abuse provided by whistleblowers, the farm was certified “organic” by the U.S. Department of Agriculture and as “Humane” by the independent nonprofit Certified Humane® program. The full report can be read at www.farmforward.com. Among the findings: A cow dragged by a skid loader more than 50 yards across concrete and gravel; Dozens of cows being trampled to death; Use of a.22 rifle to kill about 80 heifers experiencing trouble with calving; A cow’s clogged teat cut off with a rusty knife with no pain management; and Animals’ body parts left decomposing on the land, possibly contaminating the local waterways. Portions of the report were included in a story released today by The Atlantic that corroborated many of Farm Forward’s findings. Alexandre Family Farm has garnered national attention after becoming one of the first certified regenerative dairy farms in 2021. Alexandre has been featured on the Today Show, Food Network’s Guy’s All-American Road Trip, and in Forbes and the New York Times. “At a time when millions of Americans are turning away from cows’ milk, companies like Alexandre and retailers like Whole Foods are lying to the public to try and reverse the trend and protect their profits,” said Farm Forward Executive Director Andrew deCoriolis. “Dairy companies humanewash their business just like the big oil companies try to greenwash theirs. It’s a marketing spin, it’s not real change.” “Unfortunately, this investigation reveals a larger problem: organic and humane labels on meat or dairy cannot be trusted,” deCoriolis said. “Even one of the country’s most prominent and celebrated organic farms is using the same abusive and polluting agricultural practices as factory farms. Federal regulators upheld Alexandre Family Farm's organic designation even after they were given evidence that the farm was abusing animals. How many more ‘organic’ farms are out there raking in profits based on a USDA-endorsed lie?” Alexandre Family Farm touts several “ key differentiators ” that the company claims make it a better choice for dairy products, including that the way they farm is better for the cows. However, Farm Forward’s investigation revealed systematic abuse and neglect driven from the top of the company. And while Alexandre continues to profit from selling diseased and injured animals, consumers are paying a premium at Whole Foods and other groceries in support of this fraudulent vision of healthy animals and a livable climate. The investigation’s findings not only highlight violations of basic humane treatment, but also many violations of the certifications that Alexandre uses to market their products. A failure of this magnitude on the part of certification schemes like the USDA and Certified Humane calls into question whether industrial dairy farming can ever be truly compatible with a high ethical standard of animal treatment and environmental sustainability. Farm Forward is calling on Alexandre Family Farm to change its practices and its abuse of animals immediately, and is asking retailers like Whole Foods and other companies to stop purchasing Alexandre dairy and pledge to reject similar efforts at humanewashing. Farm Forward is also calling on the USDA and Certified Humane to withdraw their certifications of Alexandre Dairy and pledge to reform their internal practices to prevent humanewashing companies from gaining legitimacy through their certifications in the future. “We hope that the Alexandres, responsible retailers like Whole Foods, certifying organizations, and government regulators can all come together to fix what is broken in our agricultural system,” deCoriolis said. “Right now, there are structural problems in the dairy industry that incentivize animal abuse. We need to change that.” Concerned consumers can support Farm Forward’s push for change by signing up to join its campaign. Farm Forward also asks conscientious consumers to consider rejecting dairy products altogether. “If systemic animal mistreatment is happening at the leading higher welfare dairy, what is happening at all of the rest?” asked deCoriolis. “The only way to avoid regularly participating in these abusive practices is to opt out of dairy products altogether. Consumers are increasingly selecting plant-based dairy and could do so even more often. Consumers can also join us in pushing the agricultural sector and the federal government to do better.” ### Farm Forward is a team of strategists, campaigners, and thought leaders guiding the movement to change the way our world eats and farms. Learn more at https://www.farmforward.com/ Contact Details Farm Forward farmforward@narrativechange.net

April 12, 2024 02:37 PM Eastern Daylight Time

Comtex Launches Omnia: A Cutting-Edge News API Platform leveraging NLP and AI

Comtex

Comtex News Network, Inc (Comtex), a leading provider of news aggregation and distribution services to top firms in financial services, news publishing, syndication, and analytics, proudly announces the launch of its innovative API platform, Omnia. Omnia is a state-of-the-art API platform designed to revolutionize the way businesses access and utilize news content. Omnia empowers users with instant access to real-time streaming news, AI-generated article summaries, enhanced tagging and categorization based on NLP, advanced filtering, and access to an extensive catalog of curated news sources. Key Features of Omnia Include: Real-time Streaming News: Omnia provides real-time streaming news via websockets push and REST API for seamless integration into existing systems. Enhanced Tagging and Categorization: Leveraging AI and proprietary NLP-based algorithms, Omnia offers enhanced tagging and categorization of content, including press releases, earnings releases, product categories, and more. AI-Generated Article Summaries: Omnia utilizes AI to generate concise and searchable article summaries, enabling users to quickly grasp an article before reading it. Advanced Filtering: Omnia's advanced filtering capabilities allow users to customize their news feeds based on specific criteria, ensuring they receive only the most relevant content. Access to an extensive collection of curated, high-quality sources used by top companies in financial services, analytics, research and a broad range of industries. Omnia is designed for rapid integration and serves a variety of use cases, including training of LLMs, financial platforms, asset management, trading, academic research, legal research, market research, and much more. Commenting on the launch, Comtex CEO Kan Devnani said, "We are pleased to bring a flexible, state-of-the-art news platform with access to curated, premium news sources to market. Omnia is an extendable platform, combining AI with our rich experience applying NLP to news content. This will allow clients to derive more intelligence and insights from the news content we offer and help clients curate and identify the content most relevant to them. Comtex will use Omnia to deliver evolving analytics and insight to its users." Access to Omnia can be trialed by visiting https://www.comtex.com/api. Comtex encourages users to explore its features and capabilities. To learn more about Omnia and request a demo, please contact sales@comtex.com or visit https://www.comtex.com/api. About Comtex News Network, Inc (Comtex): Comtex News Network Inc (Comtex) is a leading provider of news aggregation services to top firms in financial services, news publishing, syndication, and analytics. With a wealth of experience and expertise, Comtex delivers comprehensive news solutions that empower businesses to make informed decisions and stay ahead of the competition. Comtex also offers syndication services to content providers and platforms to generate traffic to online content. Contact Details Comtex News Network Media Relations sales@comtex.com

April 12, 2024 02:01 PM Eastern Daylight Time

Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery

Benzinga

By Meg Flippin, Benzinga IceCure Medical Ltd. (NASDAQ: ICCM), which is set to submit results from the largest cryoablation study of its kind to the FDA, may set a new standard of care for early-stage breast cancer in women who elect not to have surgery. This could be a game-changer for the medical community and IceCure alike. When it comes to the early onset of breast cancer, the typical treatment protocol is for women to undergo a lumpectomy followed by chemotherapy, hormone or radiation therapy. The lumpectomy involves removing the tumor and some healthy tissue around it surgically in a hospital operating room. It requires heavy sedation, is often painful and has a long recovery time. While tens of thousands of lumpectomies are performed annually in the U.S., it is not a perfect solution. In about 20% of cases, a second surgical procedure known as a re-excision is required to get rid of lingering cancer cells. Some tumors are difficult to spot or feel which makes them hard to locate during the surgery and thus follow-up surgeries are often required. Re-excision can not only be costly, it adds to the recovery time and weighs on the patient’s mental health. Some women, concerned about their future, opt at that point for a mastectomy. Freezing Tumors May Be The Answer With about 280,000 women diagnosed with invasive breast cancer each year, and around 340,000 total cases, finding better alternatives is front and center for many healthcare providers, drug companies and biotechs including IceCure Medical Ltd. (NASDAQ: ICCM). IceCure is expanding the use of ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Cryoablation is a potentially attractive option for treating tumors because it is minimally invasive and has little pain associated with it. Tumors can be seen clearly by using imaging modalities like ultrasound or computerized tomography (CT), accurately destroying diseased tissue within the tumor zone. Cryoablation reduces surgery-related complications, downtime for the patient and economic burden to the insurer and the medical provider, as well as reducing the need for secondary lumpectomy in breast cancer. IceCure likens its ProSense procedure for breast tumors to that of going to the dentist, with no scarring or general anesthesia required. Rather, IceCure relies on lidocaine used locally so there is no need to go to a hospital or stay overnight to recover, all of which reduces costs and speeds up recovery. Unlike lumpectomies, cryoablation does not involve the excision of breast tissue, thereby eliminating many of the adverse cosmetic effects of tumor excision as well. Some researchers have even called cryoablation the “ultimate esthetic solution for breast cancer” because it reduces the need for pre-emptive or corrective surgical procedures to maintain or restore breast volume, contour and symmetry. For all of those reasons, breast cancer cryoablation has emerged as a possible alternative to lumpectomy for early-stage breast cancer over the past decade. Promising Topline Results IceCure recently announced positive topline results from its ICE3 study, which it says is the largest controlled multicenter clinical trial ever performed in the U.S. for liquid nitrogen (LN2) based cryoablation of low-risk, early-stage malignant breast tumors, following the five-year follow-up evaluation of the ICE3 study's last patient. In the ICE3 study, 96.39% of patients (187 out of 194 patients) were local recurrence-free with no significant device-related adverse events or complications reported. Based on those topline results, the company said ProSense has the potential to be a safe and effective alternative to lumpectomy for early-stage breast cancer. The company says it is on track to submit the full data set and results to the U.S. Food and Drug Administration (FDA) for marketing clearance any day now, and Prosense is already approved for breast cancer in other territories like Europe. The breast cancer market size is significant, and was valued at $31.89 billion in 2022 and is forecast to hit $70.53 billion by 2030, growing at a CAGR of 10.43% over 2023-2030. The tumor ablation market is expected to reach $2.4 billion by 2028, growing at a CAGR of 13.2% from now until then. "We are very pleased with this topline outcome and believe these results demonstrate a highly favorable safety and efficacy profile that positions ProSense® as a desirable alternative to lumpectomy for early-stage breast cancer," said Eyal Shamir, Chief Executive Officer of IceCure. "While the FDA evaluates the data, we are optimistic its upcoming decision will give women in the U.S. the same access as those who are already benefiting from ProSense® in other countries,” he said. ProSense has regulatory approval in 15 countries for a broad range of indications including in Europe, Brazil, Canada and China. Incidents of breast cancer are increasing around the world, with many people facing invasive and time-consuming procedures. While lumpectomies will continue to be necessary sometimes, companies like IceCure may be giving patients an alternative way to fight this disease. With full data being submitted to the FDA any day now, if approved it could prove to be game-changing for IceCure and women across America diagnosed with early-stage breast cancer. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 12, 2024 01:35 PM Eastern Daylight Time

Image

Learn The Key Differences Between Octoblock and XRP

Octoblock

By Simon Frasier Cryptocurrencies are becoming a significant pillar of the digital economy with a variety of platforms and functions that are accessible to people and investors all over the world. In this article, we go into details of two major cryptocurrencies, the Octoblock and XRP, with two different approaches and ecosystems. Understanding the differences between these two innovative forces will give investors a perception of the digital asset world, which is quite dynamic, and will help to make better decisions. What is Ripple (XRP)? Ripple is a peer-to-peer ecosystem with a differentiated ledger (a system of gateways or gates), which, unlike Bitcoin, does not use blockchain technology. At the same time, the Ripple cryptocurrency is in many ways similar to Bitcoin - it is a decentralized virtual architecture, the presence of an intra-system coin. XRP is its native cryptocurrency, and the goal of the project is to create a global network for the exchange of digital assets. According to the developers, the project was created as a kind of addition to Bitcoin, but not as a competitor. The fundamental goal is to create a global network within which clients can exchange digital assets. At the same time, the task is to increase processing speed and throughput capabilities while reducing commission fees. In addition, within the framework of XRP, the virtual structure RippleNet operates, uniting transaction providers, banking structures, and corporations. Finances sent on this network are tracked from anywhere on the planet, and an individual interface has been developed for each category of users, allowing them to solve many problems. What is Octoblock? Octoblock stands out as an innovative force, skillfully merging Game-Fi mechanics with DeFi fundamentals to redefine the landscape of decentralized finance. Positioned within the Binance Smart Chain ecosystem, Octoblock offers a multifaceted platform that pioneers engaging sweepstakes for tangible rewards, elevates yield farming with unique strategies, enables seamless cross-chain swaps for asset management across ecosystems, introduces groundbreaking Crowd Funded Yield Farming (cFyF) for enhanced returns and governance, and integrates charitable trust accounts for impactful contributions to societal causes. Technology & Supply Dynamics Octoblock and XRP are two methods of blockchain technology which are different from each other. Octoblock uses Proof-of-Stake (PoS) consensus mechanism, which majorly puts emphasis on energy efficiency and security. In contrast, Ripple makes use of Ripple Protocol Consensus Algorithm (RPCA), recognized for its ability to enable instant settlements and high throughput. These technological variants impact issues like transaction speed, scalability and energy consumption. The native tokens Octoblock and XRP, respectively, represent different tokenomics and supply dynamics. OCTO, Octoblock’s utility token, is the backbone of governance and participation in the ecosystem. Unlike XRP which has a predetermined total number of tokens, with Ripple Labs having a substantial amount of them. Understanding the tokenomics of every currency enables investors to see factors such as scarcity, inflationary pressures, and utility of each token in its own ecosystem. Community Engagement Community involvement and adoption trends instigate a different strategy for Octoblock and XRP. The Octoblock’s community development efforts are highlighted by the introduction of incentives, educational campaigns, and decentralized governance. In Ripple, the XRP token is different as it targets financial institutions and enterprises, which aims to reach widespread adoption in cross-border payment solutions. These strategies ultimately determine the market sentiment, the user base growth, and the ecosystem development. Other Major Differences between Octoblock and XRP The regulatory environment plays a pivotal role in the development of Octoblock and XRP. As a part of the Octoblock network, we adhere to and regulate the current regulatory framework, always putting user protection first. On the flipside, Ripple has been confronted with regulatory uncertainty and lawsuits which have resulted in the distortion of market dynamics and investor sentiment. Being aware of the regulatory aspects helps to identify the risks and the long-term sustainability for the cryptocurrency market.On the other hand, Investors will have to take into account different factors, as well as risks, when making up their mind about the merits of Octoblock and XRP. Such capabilities encompass technological ability, compliance with regulations, market demand, tokenomics, community support, and competitive positioning. Balancing expected returns with risk management tactics is vital for ensuring a more informed and aligned investing process with the investor's financial goals. At The End In conclusion, it is very clear that there are various cryptocurrencies around the world, and by looking at Octoblock and XRP, we can see how different they can be. Every platform has its distinct features, functionality and proposition that help the segment the market and address specific user requirements. The mentality of technology, tokenomics, community engagement, regulatory compliance, and investment considerations is the key to understanding the cryptocurrency ecosystem. This allows stakeholders to navigate the ecosystem in a more effective manner and to make decisions that are in line with their objectives. Buy OCTO: https://reef.octoblock.io/register Website: https://octoblock.io/ Discover the Premier DeFi Protocol with Integrated cFyF Technology on Binance Smart Chain - Enhance Your Yield Farming Returns Now! This post was authored by an external contributor and does not represent Benzinga’s opinions and has not been edited for content. This contains sponsored content and is for informational purposes only and not intended to be investing advice. Cryptocurrency is a volatile market; do your independent research and only invest what you can afford to lose. New token launches and small market capitalization coins are inherently more risky than large cap cryptocurrencies. These tokens are subject to larger liquidity and market risks.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Contact Details Beran Novotny support@octoblock.io Company Website https://octoblock.io/

April 12, 2024 12:00 PM Eastern Daylight Time

Image

Standard Uranium announces wraps up inaugural drill program at Atlantic Project

Standard Uranium Ltd

Standard Uranium Vice President of Exploration Sean Hillacre joined Steve Darling from Proactive to unveil the completion of the company's inaugural drilling activities at the Atlantic Project. Situated within the esteemed eastern Athabasca Basin in northern Saskatchewan, the Atlantic Project has showcased promising signs of anomalous radioactivity across all completed drill holes. In a resounding testament to the success of the program, Hillacre conveyed that anomalous radioactivity was encountered in each of the five inaugural drill holes conducted by the company. These findings have unveiled multiple zones of elevated radioactivity, closely associated with both the sub-Athabasca unconformity and basement structural zones, thereby indicating the presence of a uranium-fertile system within the project area. The results from the inaugural drilling program have not only validated the company's exploration thesis but have also underscored the immense potential of the Atlantic Project. With several kilometers of untested strike length remaining across the project area, Standard Uranium is poised to capitalize on the untapped opportunities for discovery along the E-W conductor system. Furthermore, the company is optimistic about the significant upside potential at Atlantic, particularly along the unexplored segments of the E-W conductor system. To bolster its exploration efforts, supplementary geophysical surveys are slated to be conducted over the central claim blocks. These surveys aim to delineate additional target areas for subsequent phases of drilling, while also targeting the untested gravity low anomalies identified on the western block in 2022. As Standard Uranium continues to advance its exploration endeavors at the Atlantic Project, the company remains steadfast in its commitment to unlocking the region's uranium potential. Stay tuned for further updates as Standard Uranium progresses towards its goal of resource delineation and discovery within this highly prospective region of the Athabasca Basin. Contact Details Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

April 12, 2024 10:55 AM Eastern Daylight Time

Video

Kona Gold Beverages & Apple Rush Co.: Revolutionizing Beverage Market with Joint Venture & Manufacturing Agreement

Apple Rush Company, Inc.

MELBOURNE, Fla., April 11, 2024 -- Kona Gold Beverages, Inc. (OTCPK: KGKG), a prominent holding company specializing in cutting-edge product development within the better-for-you and functional beverage sector, proudly announces its Joint Venture Agreement with Apple Rush Co., Inc. (OTC.PK: APRU). Both companies are pleased to announce a groundbreaking joint venture agreement aimed at transforming the beverage industry landscape. This strategic partnership brings together the unique capabilities of both companies to innovate, manufacture, and market a range of cutting-edge products catering to evolving consumer preferences. Kona Gold Beverages, renowned for its premium energy drinks and health-conscious offerings, joins forces with Apple Rush Co., a diversified holding company with extensive experience in farming and manufacturing within the nutraceutical space. Through its subsidiary, Lena Brewing, Apple Rush possesses the manufacturing prowess required to bring innovative beverage concepts to life. Under the terms of the agreement, Lena Brewing will play a pivotal role in manufacturing several products for Kona Gold Beverages, including the highly anticipated Kona Gold Hemps Energy Drink, Highdrate D9 Seltzer, and an exciting new functional beverage line. Apple Rush Co. commits to developing a proprietary formula for its new beverages, ensuring a blend that resonates with active lifestyles and meets stringent quality standards. "We're thrilled to embark on this transformative journey with Apple Rush Co.," said Brandon White, President of Kona Gold Beverages. "This joint venture represents a convergence of expertise, innovation, and shared vision to redefine beverage excellence. With Apple Rush's manufacturing capabilities and our commitment to delivering top-tier products, we are poised to revolutionize the industry." Apple Rush Co. CEO, David A Torgerud, echoed these sentiments, stating, "The collaboration with Kona Gold Beverages marks a significant milestone for Apple Rush and underscores our dedication to driving innovation and value creation. By leveraging our manufacturing expertise and Kona Gold's market leadership, we are well-positioned to introduce groundbreaking beverages that resonate with consumers seeking premium, plant-based alternatives." The joint venture agreement underscores the commitment of both companies to harnessing collective strengths and delivering unparalleled value to consumers. Through collaborative product development, meticulous manufacturing processes, and strategic marketing initiatives, Kona Gold Beverages and Apple Rush Co. are poised to disrupt the functional beverage market landscape. About Kona Gold Beverage, Inc. Kona Gold Beverage, Inc., operates as a holding company in the beverage industry. Through its subsidiaries, Kona Gold LLC and Covert LLC, it offers a diverse range of healthy energy drinks and products. Kona Gold's premium line of energy drinks caters to health-conscious consumers, alongside its innovative HighDrate D9 Drinks. Covert LLC specializes in high-quality products, including Delta-8, THCa, THC-P, and Kratom. Headquartered in Melbourne, Florida, Kona Gold Beverage, Inc. is actively engaged in expanding its market presence through strategic acquisitions. Investor Relations Contact: Phone: 844-714-2224 Email: investorrelations@konagoldbeverage.com For more information regarding Kona Gold Beverage, please visit: https://konagoldbeverage.com/ About The Apple Rush Company, Inc. The Apple Rush Company, Inc., through its subsidiary APRU, LLC, is a distributor of CPG products under the trademarked Apple Rush brand, Element brand and other labels. The Apple Rush brand has more than 50 years of existence in the natural beverage industry. As a historical leader in the organic and natural beverage sector our goal is to now become a leader in the distribution of anhydrous hemp oil products nationwide. For more information, please go to www.aprubrands.com, www.element-brands.com, elementk.kratomwave.store www.alkhemicalroots.com with our expanded product portfolio. For media inquiries, please contact: Investor Relations Contact: Tony Torgerud; 888-741-3777 x 2 www.aprubrands.com Safe Harbor Statement: The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. The Company may also make written or oral forward-looking statements in its filings with the U.S. Securities and Exchange Commission, in press releases and other written materials, and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Reports on Form 10-K and its other filings with the Securities and Exchange Commission. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control. The Company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise. Contact Details Tony Torgerud +1 888-741-3777 dtorgerud@aprullc.com

April 12, 2024 09:30 AM Eastern Daylight Time

News Release

Klondike Silver 2024 Drilling Program

Klondike Silver Corp.

April 12, 2024 – TheNewswire – Vancouver, Canada – Klondike Silver Corp. (the “Company”) (TSXV: KS | OTC: KLSVF | WKN: A1H8T1 ) is pleased to provide an update from its current underground drill program at the Silvana Mine, targeting western extensions of the mine within the historic Silvana claim block that the Company owns in southeastern British Columbia. Drill holes from the first phase of drilling were laid out to intersect, map and model the extensions of vein structures down dip of three mineralized lodes from surface on the Silvana Mine claims, with the intention of targeting silver, zinc, and lead mineralization in the Company’s phases of drilling. All drill cores from the 2023 program have been logged. Intervals of core have been sampled. Cores were sawed lengthwise, with one half bagged and sent to an independent lab for analyses, and one half retained for further inspection. Sample analyses are awaited from the lab. Drilling in the 2024 program is now oriented northerly from drill station 2 to intersect downward projections of the Carnation Hanging wall and Footwall Lodes. The first 2024 activity will be deepening of two holes that have been drilled part of the distance to the Hanging wall and Footwall Lodes. Klondike president and CEO, Mr. Tom Kennedy states, “The Company’s Silver Mile target is an area 1.5km along strike, 100% within Klondike’s claim block between the Mammoth and Silvana Mines. This area has yet to be fully explored due to fractured ownership that is a common theme in areas of British Columbia with significant historic mining activities dating back more than 100 years. Klondike’s management and exploration teams are encouraged by the potential to find and develop a resource in the Main Vein structure between the Mammoth and Silvana mines as combined past production of the Main Lode included 28 million oz silver, 209 million lbs zinc and 258 million lbs lead.” The technical information in this news release has been reviewed by Locke Goldsmith, M.Sc., P.Eng., P.Geo., a Q.P. Klondike’s Silvana Mine Silver Zinc Lead project is located in South Eastern B.C. Klondike’s 114 square kilometer claim block is 138 km north of the Trail B.C. smelter. Klondike Silver is exploring from underground, along the 9 km “Main Lode”. The “Main Lode” is the most prolific mineralized structure in the Slocan Mining Camp. There are 13 past producing mines that are situated along the “Main Lode” that have produced 886,000 kg of silver, 95 million kg of zinc and 117 million kg lead so far. (source: BC MINFILE). There are 67 past producing mines that are situated in Klondike Silver’s 114 square kilometer claim block. (source: BC MINFILE). On Behalf of the Board of Directors KLONDIKE SILVER CORP “Thomas J. Kennedy” CEO and Director Additional information can be found on Klondike Silver’s website: www.klondikesilver.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has not reviewed the content of this news release and therefore does not accept responsibility or liability for the adequacy or accuracy of the contents of this news release. Caution Regarding Forward-Looking Information This news release includes certain information that may constitute “ forward-looking information ” under applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, future work programs and objectives and expected results from such work programs. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information and the risks identified in the Company’s continuous disclosure record. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information contained in this news release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

April 12, 2024 09:10 AM Eastern Daylight Time

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has inked a new deal with an innovative digital health technology platform. Cardio Diagnostics’ strategic partnership with Navierre — which revolutionizes how patients access healthcare by acting as a true health companion for every stage of life — aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests. On April 1, Cardio Diagnostics’ precision heart health solutions, including its flagship AI-powered epigenetic-genetic cardiovascular risk, detection and management tests, became available to thousands of patients and clinicians on Navierre’s platform. Now, Navierre-partnered clinicians across the United States can seamlessly order these tests for their patients. Consumers can easily register for a profile on the platform by filling out a health questionnaire and requesting a test. Those clinical tests, Epi+Gen CHD and PrecisionCHD, only require a blood sample that can be collected in provider settings, at home or via mobile phlebotomy. This ease of collection will enable Cardio Diagnostics’ partnership with Navierre to leverage the growing telehealth market and revolutionize the patient cardiovascular care journey through earlier detection, accessible specialty care and personalized prevention. “We are thrilled to partner with Navierre to make our industry-leading cardiovascular clinical tests more widely available to patients and clinicians nationwide,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “Navierre’s innovative platform aligns with our mission to transform cardiovascular care through AI-driven precision diagnostics and personalized prevention strategies.” Cardiovascular Market Growth Nearly 50% of Americans live with diabetes, obesity, hypertension or another major cardiovascular risk, according to the Centers for Disease Control and Prevention (CDC). Cardiovascular disease is the leading cause of death worldwide, accounting for nearly 19 million deaths annually. This impact on a growing number of people across the world means the demand for cardiovascular diagnostics has never been higher. Companies in the field are in a position to achieve robust growth as they strive to meet the demand. Projections indicate a Compound Annual Growth Rate (CAGR) of 5.1% in the cardiovascular diagnostics market, whose market valuation is expected to reach $9.7 billion by 2033. This surge can be attributed to the escalating demand for sophisticated and accessible diagnostic technologies in the fight against cardiovascular diseases. Following this upward trend, the digital health and telehealth markets are poised for growth that has been fueled by the rapid adoption of telehealth services and the integration of AI technologies. The AI healthcare market, which is also poised for significant growth, had an estimated size of $22.45 billion in 2023, a number that’s expected to accelerate at a CAGR of 36.4%. Finally, the telehealth market, with a valuation of $128.12 billion in 2022, is forecasted to quadruple by 2030 to $504.24 billion. These developments have changed the healthcare landscape and underscore the Cardio Diagnostics-Navierre partnership’s positioning to capitalize on these market shifts. Navierre provides a digital health platform that can integrate Cardio Diagnostics’ tests into a broader telehealth ecosystem, expanding access and facilitating earlier cardiovascular risk detection. That means the flexibility of Cardio Diagnostics’ tests will pave the way for rapid nationwide scaling with minimal infrastructure barriers. Thus, the partnership could make specialty cardiology care more readily available for all communities, including those that are often underserved. By expanding the sites of care to telehealth and remote-enabled provider organizations, this partnership addresses the critical issue of increasing wait times for specialty care while democratizing access to top-tier heart disease services. This collaboration directly responds to current diagnostic methods' limitations, offering a scalable solution that extends to remote zip codes in the U.S. Advances In The Fight Against The Top Cause Of Death The COVID-19 pandemic has accelerated the adoption of digital health solutions, with the CDC reporting that 36% of adults used telehealth services in 2021. McKinsey & Company estimates that up to $250 billion of U.S. healthcare spending could be virtualized, representing about 20% of all Medicare, Medicaid and commercial outpatient, office and home health expenditures. This shift to digital health and AI-driven diagnostics could have a broad impact on the cardiovascular detection, care and management industry. Across the country, there is a need for more accessible and systemic healthcare solutions. This new partnership offers an important response to the goal of combating cardiovascular diseases globally while committing to health equity and access. “Cardio Diagnostics’ groundbreaking testing solutions are an exciting addition to our curated list of products and services we offer to our users,” said Mustafa Dinani, CEO and co-founder of Navierre. “By combining our innovative platform with their AI-driven precision diagnostics, we empower patients and clinicians with the tools they need to identify cardiovascular risk early when it can be most effectively addressed. Together, we are making significant strides in the fight against the world’s leading cause of death,” he said. Featured photo by Ali Hajiluyi on Unsplash Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

April 12, 2024 08:45 AM Eastern Daylight Time

Image

1 ... 269 270 271 272 273 ... 3753

Back